Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Moderna, Inc.
  6. News
  7. Summary
    MRNA   US60770K1079

MODERNA, INC.

(MRNA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

WHO estimates COVID-19 boosters needed yearly for most vulnerable

06/24/2021 | 10:47am EDT

* Under indicative base case 12 bln doses produced in 2022

* General population to need booster every 2 years -WHO document

* Global output ranges between 6 bln and 16 bln doses

* In worst-case scenario annual boosters for all

BRUSSELS, June 24 (Reuters) - The World Health Organization (WHO) forecasts that people most vulnerable to COVID-19, such as the elderly, will need to get an annual vaccine booster to be protected against variants, an internal document seen by Reuters shows.

The estimate is included in a report, which is to be discussed on Thursday at a board meeting of Gavi, a vaccine alliance that co-leads the WHO's COVID-19 vaccine programme COVAX. The forecast is subject to changes and is also paired with two other less likely scenarios.

Vaccine makers Moderna Inc and Pfizer Inc, with its German partner BioNTech, have been vocal in their view that the world will soon need booster shots to maintain high levels of immunity, but the evidence for this is still unclear.

The document shows that the WHO considers annual boosters for high-risk individuals as its "indicative" baseline scenario, and boosters every two years for the general population.

It does not say how these conclusions were reached, but shows that under the base scenario new variants would continue to emerge and vaccines would be regularly updated to meet these threats.

The U.N. agency declined to comment on the content of the internal document while Gavi did not immediately respond to a request for comment.

The document, which is dated June 8 and is still "work in progress", also predicts under the base case that 12 billion COVID-19 vaccine doses will be produced globally next year.

That would be slightly higher than the forecast of 11 billion doses for this year cited by the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), signalling that the U.N. agency does not expect a significant ramp-up of vaccine production in 2022.

The document predicts manufacturing problems, regulatory approval issues and "transition away from some technology platforms" as potential drags on supplies next year.

It does not signal which technologies could be phased out, but the European Union, which has reserved the world's largest volume of COVID-19 vaccines, has bet heavily on shots using messenger RNA (mRNA) technology, such as those by Pfizer and Moderna, and has forgone some purchases of viral vector vaccines from AstraZeneca and Johnson & Johnson.

WORST-CASE SCENARIO

The scenarios will be used to define the WHO's global vaccination strategy and the forecasts may change as new data emerge on the role of boosters and the duration of vaccine protection, Gavi says in another document, also seen by Reuters.

So far about 2.5 billion doses have been administered worldwide, mostly in rich countries where over half of the population has received at least one dose, whereas in many poorer countries less than 1% has been vaccinated, according to Gavi's estimates.

This gap could widen next year under the WHO's most pessimistic forecast, as the need for annual boosters could push once again poorer nations to the back of the queue.

In its worst-case scenario, the U.N. agency says production would be 6 billion doses next year, due to stringent regulation for new shots and manufacturing issues with existing ones.

That could be compounded by the need for annual boosters for the entire world, and not just the most vulnerable, to combat variants and limited duration of protection.

In the more optimistic situation, all vaccines in the pipeline would get authorised and production capacity would ramp up to about 16 billion doses to meet demand. Vaccines would also be shared equitably across the world.

There would be no need for boosters as vaccines would show strong efficacy against variants and long protection.

(Reporting by Francesco Guarascio @fraguarascio; Editing by Josephine Mason and Emelia Sithole-Matarise)


ę Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC 0.83% 8339 Delayed Quote.12.92%
BIONTECH SE -2.30% 404.92 Delayed Quote.396.71%
MODERNA, INC. -0.67% 416.26 Delayed Quote.301.12%
PFIZER, INC. -0.29% 45.06 Delayed Quote.22.41%
All news about MODERNA, INC.
05:13pHealth Care Down On Cyclical Bias -- Health Care Roundup
DJ
04:17pMODERNA : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULT..
AQ
04:10pNOVAVAX : again delays seeking U.S. approval for COVID-19 vaccine
RE
03:06pMODERNA : says COVID-19 shot maintains high efficacy through 6 months, sees even..
RE
02:07pMODERNA : U.S. administers nearly 349 mln doses of COVID-19 vaccines - CDC
RE
02:02pMODERNA : U.S. CDC Says Administered 348.97 Million Doses Of Covid-19 Vaccine As..
RE
12:16pMODERNA : says its COVID-19 shot maintains high efficacy through 6 months
RE
11:39aGLOBAL MARKETS LIVE : Robinhood, Bayer, MetLife, Uber, WPP...
11:25aModerna says vaccine is 93% effective six months later
RE
11:05aTHE LATEST : Moderna plans booster doses to help fight virus
AQ
More news
Financials (USD)
Sales 2021 19 117 M - -
Net income 2021 10 725 M - -
Net cash 2021 11 948 M - -
P/E ratio 2021 16,5x
Yield 2021 -
Capitalization 167 B 167 B -
EV / Sales 2021 8,12x
EV / Sales 2022 9,22x
Nbr of Employees 1 300
Free-Float 90,3%
Chart MODERNA, INC.
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 17
Last Close Price 416,26 $
Average target price 187,80 $
Spread / Average Target -54,9%
EPS Revisions
Managers and Directors
StÚphane Bancel Chief Executive Officer & Director
Stephen Hoge President
David W. Meline Chief Financial Officer
Noubar B. Afeyan Chairman
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capi. (M$)
MODERNA, INC.301.12%168 260
LONZA GROUP AG26.76%59 023
IQVIA HOLDINGS INC.39.45%47 876
CELLTRION, INC.-25.07%32 166
SEAGEN INC.-6.81%29 694
PHARMARON BEIJING CO., LTD.94.07%26 319